Cagrilintide vs Semaglutide: Different Paths

Cagrilintide and semaglutide are not competitors — they are complements. They target completely different receptor systems (amylin vs GLP-1), activate different brain regions, and when combined, produce weight loss that exceeds what either achieves alone.

This comparison breaks down what each does, how they differ, and why their combination (CagriSema) may represent the next leap in obesity pharmacotherapy.

Quick Comparison

Mechanism: Two Separate Pathways

This is the critical distinction. Cagrilintide and semaglutide are not two versions of the same thing — they work through fundamentally different receptor systems.

Cagrilintide: The Amylin Pathway

Cagrilintide is an acylated analog of human amylin with a ~160-hour half-life (native amylin lasts ~15 minutes). It activates amylin receptors 1 and 3 (AMY1R/AMY3R) — heterodimers of the calcitonin receptor with receptor activity-modifying proteins (Lau et al., 2021).

Primary action sites: area postrema and nucleus of the solitary tract (NTS) in the brainstem. These regions process satiety signals from the gut and produce the "I've had enough" feeling during and after meals.

Semaglutide: The GLP-1 Pathway

Semaglutide is a GLP-1 receptor agonist with 94% homology to native GLP-1 and a ~7-day half-life achieved through C18 fatty acid acylation and DPP-4 resistance (Muller et al., 2021).

Primary action sites: hypothalamus (arcuate nucleus, paraventricular nucleus) and NTS. These regions regulate energy homeostasis, hunger/satiety set points, and reward-related eating behavior.

Why the Distinction Matters

The overlap at the NTS is notable — both pathways converge there. But cagrilintide engages the area postrema (which semaglutide does not primarily target) while semaglutide engages the hypothalamus (which cagrilintide does not primarily target). The result is broader brain coverage of appetite regulation circuits than either agent alone.

Weight Loss: Monotherapy Comparison

Comparing these head-to-head as monotherapies requires some context, because the pivotal trials differed in duration and design.

Cagrilintide Monotherapy (Phase 2)

The Lau et al. (2021) trial tested cagrilintide at 0.3-4.5 mg weekly for 26 weeks in 706 adults:

(Lau et al., 2021)

Semaglutide Monotherapy (Phase 3)

The STEP 1 trial tested semaglutide 2.4 mg weekly for 68 weeks in 1,961 adults:

• Mean weight loss: -14.9%

• =10% threshold: ~70%

• =15% threshold: ~54%

• =20% threshold: ~32%

Important caveat: The semaglutide trial was 68 weeks versus only 26 weeks for cagrilintide. Weight loss with GLP-1 agonists continues accumulating through week 60+. A fair comparison would require same-duration data, which does not exist for monotherapy. Cagrilintide at 26 weeks may not have reached its full weight loss potential.

That said, semaglutide's absolute numbers at any timepoint comparison are higher. As monotherapy, semaglutide appears to be the more potent weight loss agent.

The Combination: CagriSema

The real clinical story is not monotherapy versus monotherapy — it is the combination.

REDEFINE 1 Results (Phase 3)

The landmark trial randomized 3,417 adults to CagriSema 2.4/2.4 mg, semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo for 68 weeks (Aronne et al., 2025):

The combination significantly outperformed either component alone. The additive effect validates the biological hypothesis: amylin and GLP-1 engage overlapping but distinct neural circuits, and activating both produces a synergistic response that neither achieves independently.

REDEFINE 2 (Type 2 Diabetes)

In patients with T2D, CagriSema produced significant weight loss alongside glycemic improvements (HbA1c reduction), outperforming the individual components (Lingvay et al., 2025).

Side Effect Comparison

Both agents share gastrointestinal side effects as their primary tolerability issue.

A notable finding from CagriSema trials: the GI side effect profile of the combination was similar to semaglutide monotherapy, not meaningfully worse. The titration protocol (16 weeks for both components) effectively manages tolerability despite dual mechanism activation (Enebo et al., 2021).

Both share theoretical concerns about pancreatitis (rare) and gallbladder events (related to rapid weight loss). The thyroid C-cell tumor boxed warning applies to GLP-1 agonists like semaglutide; its relevance to amylin analogs like cagrilintide is uncertain.

Availability and Regulatory Status

This is the most practical difference for most people right now.

Semaglutide:

• FDA-approved for weight management (2021) and type 2 diabetes
• Widely available via prescription
• Available from research peptide suppliers
• Established insurance coverage pathways
• Years of post-marketing safety data

Cagrilintide:

• Not FDA-approved (investigational as of March 2026)
• Phase 3 REDEFINE trials complete with positive results
• Available from some research peptide suppliers as a research chemical
• No insurance coverage
• Limited long-term safety data (68 weeks maximum from trials)

Cost Considerations

Without FDA approval, cagrilintide has no established retail price. Research-grade cagrilintide from peptide suppliers varies significantly by vendor and may not match the pharmaceutical-grade material used in clinical trials.

Semaglutide's prescription cost ranges from $1,000-1,400/month retail, with significant variation by insurance and pharmacy. Research-grade semaglutide is widely available at lower cost points.

The CagriSema combination, if approved, would likely be priced at a premium to semaglutide alone — reflecting its superior efficacy and Novo Nordisk's development investment.

The Verdict

This is not really an either/or decision. Cagrilintide and semaglutide occupy different pharmacological niches and are designed to work together.

If you can only choose one: Semaglutide. It is FDA-approved, widely available, has years of safety data, produces substantial weight loss as monotherapy, and has demonstrated cardiovascular benefit in the SELECT trial.

If maximizing weight loss is the goal: CagriSema. The 22.7% weight loss with 60% of participants hitting the 20% threshold approaches bariatric surgery territory. No other pharmacotherapy combination comes close.

If you have plateaued on semaglutide: Adding cagrilintide targets a pathway semaglutide does not reach. The clinical data supports this as a rational escalation strategy, though it requires access to investigational cagrilintide.

For type 2 diabetes with obesity: CagriSema provides dual benefit — superior weight loss plus enhanced glycemic control through complementary mechanisms.

Who should wait: If you are considering cagrilintide, be aware that it remains investigational. Research-grade products may differ from the pharmaceutical material used in clinical trials. Regulatory approval (if granted) would provide quality assurance and prescriber guidance that research-grade use cannot.

Frequently Asked Questions

Is cagrilintide better than semaglutide?

As monotherapy, semaglutide produces more weight loss. But the comparison misses the point — cagrilintide's primary value is in combination with semaglutide (CagriSema), where the two pathways together produce 22.7% weight loss versus ~15-17% with semaglutide alone.

Can cagrilintide and semaglutide be used together?

Yes. This is the CagriSema combination studied in the REDEFINE Phase 3 program. In clinical trials, they were co-formulated in a single pen. For research purposes, they can be administered as separate injections at different sites on the same day.

Is cagrilintide FDA-approved?

No. As of March 2026, cagrilintide remains investigational. Phase 3 results are positive, and Novo Nordisk is pursuing regulatory approval for the CagriSema combination.

Related Reading

• Cagrilintide Benefits — 6 effects with clinical trial data
• Cagrilintide Dosing Guide — titration, reconstitution, and protocols
• Semaglutide Benefits — 8 proven effects
• Semaglutide Dosing Guide — weekly dosing and titration
• Liraglutide vs Semaglutide — head-to-head GLP-1 comparison
• Retatrutide Dosing Guide — triple agonist approach

References

For educational and research purposes only. This is not medical advice. Semaglutide is FDA-approved; cagrilintide is investigational and not FDA-approved. Consult your healthcare provider for personalized guidance.